NCT04504331 2026-02-12Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast CancerStanford UniversityPhase 1 Terminated4 enrolled 11 charts
NCT00584233 2022-12-06Evaluation of Breast CTUniversity of California, DavisPhase NA Completed75 enrolled 7 charts